Nanotherapy Shrinks Artery Plaque in Mice
A targeted nanoimmunotherapy reduced atherosclerotic plaque burden and appeared to stabilize plaques in a mouse study.
Updated on Nov. 4, 2026 in Heart Disease
Researchers developed a targeted nanoimmunotherapy that reduced atherosclerotic plaque burden in mice. Treated plaques showed smaller necrotic cores and larger collagen cap areas, consistent with greater stability.
Why it matters
Macrophage clearance of dead cells becomes impaired in advanced plaques, and inflammation drives plaque progression and instability. The approach targets these processes directly, though results so far come from animal experiments only.
The study measured aortic plaque coverage in mice, with treated animals at 9.4% versus 32.4% for saline controls after twice-weekly intravenous dosing over 12 weeks. Whether these results translate to human arteries remains unknown.
The details
The platform combines phosphorene nanosheets, modified with the collagen IV-binding peptide KC11 and loaded with the immune-modulating molecule Resolvin D1. The formulation accumulated in plaques and was taken up by lesional macrophages, improving efferocytosis and shifting cells toward an M2-like phenotype. No obvious toxicity was observed under the conditions tested.
Timeline
The twice-weekly intravenous treatment course in mice lasted 12 weeks.
Roadmap
Research on macrophage efferocytosis has increasingly focused on why clearance fails in advanced lesions, and this study tests whether restoring it can reduce plaque burden. The work moves that line of inquiry from mechanism toward a candidate therapeutic approach, though it remains preclinical.
For readers managing heart disease, this study does not yet change treatment options, since it has only been tested in mice. Any future therapy would need human trials before affecting daily care or access.
The takeaway
Plaque stability, not just size, may determine heart attack risk, and this study targets stability directly. Human safety and effectiveness must still be proven before any clinical use.
Further reading
Explore more on Heart Disease and how plaque buildup develops over time.
More information
Read the full Acta Pharmaceutica Sinica B article on nanoimmunotherapy for the complete methods and results.
